518 related articles for article (PubMed ID: 23665285)
1. SUOX is a promising diagnostic and prognostic biomarker for hepatocellular carcinoma.
Jin GZ; Yu WL; Dong H; Zhou WP; Gu YJ; Yu H; Yu H; Lu XY; Xian ZH; Liu YK; Cong WM; Wu MC
J Hepatol; 2013 Sep; 59(3):510-7. PubMed ID: 23665285
[TBL] [Abstract][Full Text] [Related]
2. Leukemia inhibitory factor receptor is a novel immunomarker in distinction of well-differentiated HCC from dysplastic nodules.
Luo Q; Zhang Y; Wang N; Jin G; Jin H; Gu D; Tao X; Huo X; Ge T; Cong W; Wang C; Qin W
Oncotarget; 2015 Mar; 6(9):6989-99. PubMed ID: 25749520
[TBL] [Abstract][Full Text] [Related]
3. A Large-Scale Multicenter Study Validates Aldo-Keto Reductase Family 1 Member B10 as a Prevalent Serum Marker for Detection of Hepatocellular Carcinoma.
Ye X; Li C; Zu X; Lin M; Liu Q; Liu J; Xu G; Chen Z; Xu Y; Liu L; Luo D; Cao Z; Shi G; Feng Z; Deng H; Liao Q; Cai C; Liao DF; Wang J; Jin J; Cao D
Hepatology; 2019 Jun; 69(6):2489-2501. PubMed ID: 30672601
[TBL] [Abstract][Full Text] [Related]
4. AKR1B10 expression is associated with less aggressive hepatocellular carcinoma: a clinicopathological study of 168 cases.
Schmitz KJ; Sotiropoulos GC; Baba HA; Schmid KW; Müller D; Paul A; Auer T; Gamerith G; Loeffler-Ragg J
Liver Int; 2011 Jul; 31(6):810-6. PubMed ID: 21645211
[TBL] [Abstract][Full Text] [Related]
5. Impact of aldo-keto reductase family 1 member B10 on the risk of hepatitis C virus-related hepatocellular carcinoma.
Sato S; Genda T; Ichida T; Murata A; Tsuzura H; Narita Y; Kanemitsu Y; Ishikawa S; Kikuchi T; Mori M; Hirano K; Iijima K; Wada R; Nagahara A; Watanabe S
J Gastroenterol Hepatol; 2016 Jul; 31(7):1315-22. PubMed ID: 26758591
[TBL] [Abstract][Full Text] [Related]
6. The significance of MMP-9 over MMP-2 in HCC invasiveness and recurrence of hepatocellular carcinoma after curative resection.
Chen R; Cui J; Xu C; Xue T; Guo K; Gao D; Liu Y; Ye S; Ren Z
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S375-84. PubMed ID: 21681378
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemistry Detects Increased Expression of Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) in Early-Stage Hepatocellular Carcinoma.
Han C; Gao L; Zhao L; Sheng Q; Zhang C; An Z; Xia T; Ding Y; Wang J; Bai H; Dou X
Med Sci Monit; 2018 Oct; 24():7414-7423. PubMed ID: 30328412
[TBL] [Abstract][Full Text] [Related]
8. Identification and expression analysis of the aldo-ketoreductase1-B10 gene in primary malignant liver tumours.
Heringlake S; Hofdmann M; Fiebeler A; Manns MP; Schmiegel W; Tannapfel A
J Hepatol; 2010 Feb; 52(2):220-7. PubMed ID: 20036025
[TBL] [Abstract][Full Text] [Related]
9. Up-regulated aldo-keto reductase family 1 member B10 in chronic hepatitis C: association with serum alpha-fetoprotein and hepatocellular carcinoma.
Sato S; Genda T; Hirano K; Tsuzura H; Narita Y; Kanemitsu Y; Kikuchi T; Iijima K; Wada R; Ichida T
Liver Int; 2012 Oct; 32(9):1382-90. PubMed ID: 22681639
[TBL] [Abstract][Full Text] [Related]
10. High preoparative levels of serum periostin are associated with poor prognosis in patients with hepatocellular carcinoma after hepatectomy.
Lv Y; Wang W; Jia WD; Sun QK; Huang M; Zhou HC; Xia HH; Liu WB; Chen H; Sun SN; Xu GL
Eur J Surg Oncol; 2013 Oct; 39(10):1129-35. PubMed ID: 23916473
[TBL] [Abstract][Full Text] [Related]
11. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study.
Shen Q; Fan J; Yang XR; Tan Y; Zhao W; Xu Y; Wang N; Niu Y; Wu Z; Zhou J; Qiu SJ; Shi YH; Yu B; Tang N; Chu W; Wang M; Wu J; Zhang Z; Yang S; Gu J; Wang H; Qin W
Lancet Oncol; 2012 Aug; 13(8):817-26. PubMed ID: 22738799
[TBL] [Abstract][Full Text] [Related]
12. The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma.
Di Tommaso L; Destro A; Seok JY; Balladore E; Terracciano L; Sangiovanni A; Iavarone M; Colombo M; Jang JJ; Yu E; Jin SY; Morenghi E; Park YN; Roncalli M
J Hepatol; 2009 Apr; 50(4):746-54. PubMed ID: 19231003
[TBL] [Abstract][Full Text] [Related]
13. Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis.
Giannini EG; Marenco S; Borgonovo G; Savarino V; Farinati F; Del Poggio P; Rapaccini GL; Anna Di Nolfo M; Benvegnù L; Zoli M; Borzio F; Caturelli E; Chiaramonte M; Trevisani F;
Hepatology; 2012 Oct; 56(4):1371-9. PubMed ID: 22535689
[TBL] [Abstract][Full Text] [Related]
14. Aldo-Keto Reductases as Early Biomarkers of Hepatocellular Carcinoma: A Comparison Between Animal Models and Human HCC.
Torres-Mena JE; Salazar-Villegas KN; Sánchez-Rodríguez R; López-Gabiño B; Del Pozo-Yauner L; Arellanes-Robledo J; Villa-Treviño S; Gutiérrez-Nava MA; Pérez-Carreón JI
Dig Dis Sci; 2018 Apr; 63(4):934-944. PubMed ID: 29383608
[TBL] [Abstract][Full Text] [Related]
15. The beta2-adrenergic receptor is a potential prognostic biomarker for human hepatocellular carcinoma after curative resection.
Chen D; Xing W; Hong J; Wang M; Huang Y; Zhu C; Yuan Y; Zeng W
Ann Surg Oncol; 2012 Oct; 19(11):3556-65. PubMed ID: 22588469
[TBL] [Abstract][Full Text] [Related]
16. Golgi protein 73, not Glypican-3, may be a tumor marker complementary to α-Fetoprotein for hepatocellular carcinoma diagnosis.
Wang Y; Yang H; Xu H; Lu X; Sang X; Zhong S; Huang J; Mao Y
J Gastroenterol Hepatol; 2014 Mar; 29(3):597-602. PubMed ID: 24236824
[TBL] [Abstract][Full Text] [Related]
17. iTRAQ-2DLC-ESI-MS/MS based identification of a new set of immunohistochemical biomarkers for classification of dysplastic nodules and small hepatocellular carcinoma.
Jin GZ; Li Y; Cong WM; Yu H; Dong H; Shu H; Liu XH; Yan GQ; Zhang L; Zhang Y; Kang XN; Guo K; Wang ZD; Yang PY; Liu YK
J Proteome Res; 2011 Aug; 10(8):3418-28. PubMed ID: 21631109
[TBL] [Abstract][Full Text] [Related]
18. Combination of osteopontin with peritumoral infiltrating macrophages is associated with poor prognosis of early-stage hepatocellular carcinoma after curative resection.
Zhu W; Guo L; Zhang B; Lou L; Lin Z; Zhu X; Ren N; Dong Q; Ye Q; Qin L
Ann Surg Oncol; 2014 Apr; 21(4):1304-13. PubMed ID: 24366422
[TBL] [Abstract][Full Text] [Related]
19. [Expression and clinicopathologic significance of GPC3 and other antibodies in well-differentiated hepatocellular carcinoma].
DU JL; Wei LX; Wang YL
Zhonghua Bing Li Xue Za Zhi; 2011 Jan; 40(1):11-6. PubMed ID: 21429352
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma.
Waidmann O; Köberle V; Bettinger D; Trojan J; Zeuzem S; Schultheiß M; Kronenberger B; Piiper A
J Hepatol; 2013 Oct; 59(4):769-79. PubMed ID: 23792028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
